NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Diagnostics & Research · USD

Fulgent Genetics, Inc. (FLGT) Stock Analysis

Fulgent Genetics, Inc. (FLGT) is a Diagnostics & Research stock listed on NASDAQ and quoted in US Dollar.

FLGT

$19.73

+$0.08 (+0.41%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare FLGT with… →

FLGT Key Statistics

As of Sep 4, 2026
Trading
Open
$19.54
Previous Close
$19.65
Day's Range
19.38–19.86
52-Week Range
13.46–31.04
Volume
225.00K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.93
Valuation
Market Cap
$542.88M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
1.68
EPS (ttm)Profit attributable to each share over the last twelve months.
−2.84
Financials (FY)
Revenue (FY)
$322.67M+13.83%
Net Income (FY)
−$60.51M
Profit marginThe share of revenue left as profit after all costs and taxes.
−26.05%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
27.52M
1-Year Return
−10.24%
Dividend and dates
Earnings Date
November 6, 2026
Avg Volume
285.74K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

FLGT Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−24.90%
2025+42.23%
2024−36.11%
2023−2.92%
2022−70.39%
2021+93.07%
2020+303.88%
2019+306.94%
2018−27.63%
2017−62.14%
2016 (partial year)+26.03%

As of September 4, 2026.

FLGT Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$322.67M−$60.51M−18.8%
2024$283.47M−$42.71M−15.1%
2023$289.21M−$167.83M−58.0%
2022$618.97M$143.40M23.2%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$322.67M$130.88M−$91.10M−$60.51M−18.8%
2024$283.47M$107.22M−$73.92M−$42.71M−15.1%
2023$289.21M$104.46M−$75.30M−$167.83M−58.0%
2022$618.97M$366.90M$181.50M$143.40M23.2%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

FLGT Valuation vs Diagnostics & Research Median

Median of 49 stocks
MetricFLGTDiagnostics & Research medianvs median
P/S ratio1.684.9966% below
Profit margin−26.05%0.00%26.0 pts below

Medians across 49 Diagnostics & Research stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Fulgent Genetics, Inc. (FLGT) at $542.88M. It is classified in the Diagnostics & Research industry, within the Healthcare sector. Headcount on file is 1,315.

FLGT last closed at $19.73 on September 4, 2026. That is +$0.08 (+0.41%) against the previous close. The 52-week range on file runs from $13.46 to $31.04. The latest close sits 46.58% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $322.67M. That is +13.83% against the prior fiscal year, when revenue was $283.47M. The same year closed with a net loss of $60.51M. The reported profit margin is −26.05%. That is 26 percentage points below the Diagnostics & Research median of 0%. Earnings per share on a trailing basis come to −2.84.

Across the 4 fiscal years on file, revenue moves from $618.97M in 2022 to $322.67M in 2025. Of those 4 years, 1 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. The price-to-sales ratio is 1.68. On price-to-sales that is 66.42% below the Diagnostics & Research median of 4.99. The medians here are taken across 49 Diagnostics & Research companies that report the metric.

The reported beta is 0.93. Daily returns over the trailing 9 years annualize to a volatility of 75.47%. Over the trailing twelve months the price has returned −10.24%. Measured over 5 years, that is −26.82% a year compounded.

Growth & Income

The record shows no dividend for FLGT.

The strongest complete calendar year on file is 2019 at +306.94%; the weakest is 2022 at −70.39%. Of the 9 complete calendar years on file, 4 finished higher. So far in 2026 the price is −24.90%.

Peer Comparison

Fulgent Genetics, Inc. (FLGT) operates in the Diagnostics & Research industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Fulgent Genetics, Inc. FLGT $542.88M —
Thermo Fisher Scientific Inc. TMO $226.94B 33.0
Danaher Corporation DHR $145.98B 37.0
Natera, Inc. NTRA $47.31B —

The Diagnostics & Research industry average P/E ratio is 33.1x. Fulgent Genetics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Diagnostics & Research Stocks

TMO

Thermo Fisher Scientific Inc.

$226.94B

 DHR

Danaher Corporation

$145.98B

 NTRA

Natera, Inc.

$47.31B

 IQV

IQVIA Holdings Inc.

$44.07B

 A

Agilent Technologies, Inc.

$42.54B

 IDXX

IDEXX Laboratories, Inc.

$42.18B
View all Diagnostics & Research stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Fulgent Genetics, Inc.

Fulgent Genetics, Inc. provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The company operates picture genetics platform, which includes gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, large corporations, and patients. Fulgent Genetics, Inc. was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. The company was founded in 2011 and is headquartered in El Monte, California.

Visit website →